Notable People in R&D
High achievers heralded: R&D Directions' 4th annual report spotlights a diverse spectrum of pharmaceutical research contributors.
By Michael D. Christel

R&D Hotspots (A supplement to R&D Directions)
Asia Pacific
Region ripe for clinical research Drug developers eye diverse Asia-Pacific destinations as key vehicles for growth
By Lyle Fitzsimmons
 

Editor's Page
For research scientists in large pharma R&D organizations, the cuts at Pfizer, AstraZeneca, and GlaxosmithKline signal an irreversible trend in the industry
By Christiane Truelove

R&D Business
Joe Jimenez succeeds Daniel Vasella as CEO of Novartis, as the company seeks takeover of eye-care giant Alcon Inc.
By Colette Pilkus

Drugs in Development
Pfi zer signs development deal focused on protein-protein interaction therapeutic targets.
By Colette Pilkus

Filed for Approval
Shire Plc. submits U.S. application for Replagal, an enzyme replacement therapy for fabry disease.
By Colette Pilkus

China’s clinical-trial advantages should sustain
Ning Xu, M.D., Covance senior director and head of clinical development services, China, answered questions from R&D Directions about the accelerated emergence of China as a destination of choice for drug developers and contract research organizations.
By Michael D. Christel

Q&A: Pfizer specialty care chief
R&D Directions spoke with Geno Germano, president and general manager of Pfizer’s specialty care business unit, about the company’s new-look specialty disease pipeline since its merger with Wyeth.
By Colette Pilkus